| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 宣泰医药成立于2012年8月，是一家专注于高端药物制剂研发、商业化生产和销售的高科技型企业。公司致力于药物制剂产品的国际化，为全球市场提供高性价比的医药产品。公司成功开发多个产品于全球多地区获批上市销售，在研产品治疗领域涵盖代谢，抗肿瘤，中枢神经等。公司总部及研发中心位于上海张江药谷，配备有先进的药物制剂处方开发实验室、GMP中试车间和GMP分析实验室。全资拥有的现代化药物生产基地位于江苏海门经济开发区，占地面积5.5万平方米，涉及固体口服制剂，高活性制剂生产车间。多次通过NMPA及FDA等官方现场审计。 公司业务同时涉及高端营养品及膳食补充剂等产品的研发、生产和销售。 | ||||||||||||||||||||||||
| Main Business | 主要从事高端仿制药的研发、生产和销售以及CRO服务 | ||||||||||||||||||||||||
| Legal Representative | 郭明洁 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 李方立 | ||||||||||||||||||||||||
| Solicitors | 上海市锦天城律师事务所 | ||||||||||||||||||||||||
| Auditors | 上会会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 021-68819009-606 | ||||||||||||||||||||||||
| Fax No | 021-68819009-602 | ||||||||||||||||||||||||
| Website | www.sinotherapeutics.com | ||||||||||||||||||||||||
| info@sinotph.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 25/08/2022 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.130 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.041 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 2.670 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 1.533B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |